Peretz Avi, Naamneh Basel, Tkhawkho Linda, Nitzan Orna
1 Clinical Microbiology Laboratory, The Baruch Padeh Medical Center Poriya, Tiberias, Israel.
2 The Faculty of Medicine in the Galilee, Bar Ilan University, Zefat, Israel.
Microb Drug Resist. 2019 Apr;25(3):408-412. doi: 10.1089/mdr.2018.0393. Epub 2019 Feb 6.
Increasing antimicrobial resistance is a major problem worldwide. Many urinary tract infection (UTI) isolates are resistant to all oral antimicrobial agents, necessitating intravenous treatment even for cystitis. Fosfomycin is a broad-spectrum antibiotic that achieves high and prolonged urinary drug concentration and is considered first-line treatment for uncomplicated cystitis. Our aim was to investigate fosfomycin susceptibility among urinary isolates and search for demographic or bacterial characteristics associated with fosfomycin nonsusceptibility.
This is a retrospective study of all Gram-negative urinary isolates at Padeh-Poriya Medical Center in northern Israel. A total of 1503 isolates were tested for fosfomycin susceptibility, as well as susceptibility to other antimicrobial agents, by VITEK2 system and disk diffusion testing. Demographic and clinical data were obtained from patient electronic files.
A total of 1,503 isolates from patients' urine were included. Mean patient age was 64.6 years, 937 (62.3%) were female, 913 (60.7%) were Jews, and in 1,058 (70.4%) cases, the infection was community acquired; 28.1% were extended-spectrum beta lactamase (ESBL)-positive. A total of 1099 (73.1%) isolates were susceptible to fosfomycin. Fosfomycin nonsusceptibility was significantly correlated to year: 124 (20.7%) in 2015 versus 280 (30.9%) in 2016; patient age: 17.6% in patients ≤50 years versus 30% in patients >50 years; hospital-acquired UTI: 34.2% versus 23.8%; and presence of ESBL positivity: 31.1% in ESBL-positive versus 20.9% in ESBL-negative isolates (p for all <0.001).
Fosfomycin nonsusceptibility among urine culture isolates is a worrisome phenomenon that is on the rise and is more often found in elderly patients, patients with nosocomial UTI, and isolates that are ESBL positive.
日益增加的抗菌药物耐药性是全球范围内的一个主要问题。许多泌尿系统感染(UTI)分离株对所有口服抗菌药物均耐药,甚至膀胱炎也需要静脉治疗。磷霉素是一种广谱抗生素,可在尿液中达到高且持久的药物浓度,被认为是单纯性膀胱炎的一线治疗药物。我们的目的是调查尿液分离株对磷霉素的敏感性,并寻找与磷霉素不敏感相关的人口统计学或细菌特征。
这是一项对以色列北部帕德 - 波里亚医疗中心所有革兰氏阴性尿液分离株的回顾性研究。通过VITEK2系统和纸片扩散试验对总共1503株分离株进行了磷霉素敏感性以及对其他抗菌药物的敏感性检测。人口统计学和临床数据从患者电子档案中获取。
共纳入了1503例患者尿液分离株。患者平均年龄为64.6岁,937例(62.3%)为女性,913例(60.7%)为犹太人,1058例(70.4%)感染为社区获得性;28.1%为产超广谱β-内酰胺酶(ESBL)阳性。总共1099例(73.1%)分离株对磷霉素敏感。磷霉素不敏感与年份显著相关:2015年为124例(20.7%),2016年为280例(30.9%);患者年龄:≤50岁患者中为17.6%,>50岁患者中为30%;医院获得性UTI:34.2%对23.8%;以及ESBL阳性情况:ESBL阳性分离株中为31.1%,ESBL阴性分离株中为20.9%(所有p值均<0.001)。
尿液培养分离株中磷霉素不敏感是一个令人担忧的现象,且呈上升趋势,在老年患者、医院获得性UTI患者以及ESBL阳性分离株中更常见。